Callio Therapeutics Begins Phase I Trial, Dosing First Patient with Dual‑Payload ADC CLIO‑8221 for Advanced HER2‑Positive Solid Tumors

Callio Therapeutics is actively developing a pipeline of promising dual-payload ADCs featuring rationally designed payload combinations for hard-to-treat tumors CLIO-8221... Read More

The post Callio Therapeutics Begins Phase I Trial, Dosing First Patient with Dual‑Payload ADC CLIO‑8221 for Advanced HER2‑Positive Solid Tumors appeared first on citybiz.